[Research Report] The aptamers technology market size is projected to grow from US$ 2,168.8 million in 2022 to US$ 9,803.8 million by 2030; the market is estimated to record a CAGR of 20.8% during 2022–2030.

Market Insights and Analyst View:

Aptamers are preferred from libraries of arbitrary oligonucleotide sequences in multiple rounds of irregular partitioning and PCR amplification. More than ten sequences are typically required for the aptamers selection. There are two main techniques to create aptamers: the Systemic Evolution of Ligands (SELEX) method and the non-SELEX technique. The SELEX method has six main steps: generating a single-stranded oligonucleotide library, targeting a randomized oligonucleotide incubation library with the target, binding sequence elution and amplification, obtaining single-stranded DNA following the PCR amplification, counter or negative selection, and tracking selection progression. The sequences produced are analyzed, and the classified sequences found at the highest percentages are the potential aptamers. Genomic SELEX, spiegelmer, photo SELEX, in silico-SELEX, in vivo SELEX, monoLEX, and whole cell-SELEX are variations of the SELEX method.

 The scope of the aptamers technology market includes technique, type, applications, end users, and geography. The market for Aptamers Technology is analyzed based on major countries such as North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and South & Central America (SCAM).

Key driving factors such as the growing healthcare facilities for chronic diseases in emerging markets and increasing clinical trials by healthcare providers for developing aptamer-based therapeutics with the help of aptamers are helping the market grow. Furthermore, growing venture capital funding for research on aptamers and collaboration with pharmaceutical companies and research institutes also provide opportunities for the growth of the aptamer technology market. For instance, in 2021, Aptamer Group, the Optimer reagents and therapeutics developer, announced their current agreement extension with AstraZeneca, a global biopharmaceutical company. This agreement evaluates the potential of using Optimer-based strategies to target renal cells and explores the probability of developing next-generation drug delivery vehicles, Optimer-drug conjugates. This agreement extension will further allow Aptamer Group’s expertise and knowledge in developing aptamer-based technologies with AstraZeneca’s leadership in developing cardiovascular, renal, and Metabolic (CVRM) therapy.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Aptamers Technology Market: Strategic Insights

Market Size Value in	US$ 2,168.8 million in 2022
Market Size Value by	US$ 9,803.8 million by 2030
Growth rate	CAGR of 20.8% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Growth Drivers:

Advantages Over Monoclonal Antibodies Propels Aptamers Market Growth

As compared to aptamers, monoclonal antibodies have certain limitations. Aptamers perform better in targeting small molecules (30 to 60 nt). Furthermore, monoclonal antibodies are sensitive to temperature, and aptamers are stable at room temperature and have a longer shelf life. The denaturation is reversible. Additionally, antibodies are developed by building an immune response in an animal prototype or recombinant DNA technology.

On the other hand, aptamers can be synthesized using less expensive chemical methods. Therefore, aptamers are more fascinating for developing new therapeutic drugs and diagnostic kits. Also, aptamers are selected in vitro by a method that might include positive and negative selection steps, thus ensuring high specificity. Only a few nanomoles are required for selection, and a large molecular diversity is screened. Large antibody size limits membrane permeability, creating difficulties when targeting dense tissue. Unique bi-specific antibodies have been persuaded to cross the blood-brain barrier, but traditional antibodies cannot. Small antibodies (~90 kDa) have been isolated from llamas, sharks, and camels. Fragments of these small antibodies, termed nanobodies (~ 15 kDa), show promise as affinity agents but are not widely accessible.

Aptamers have revealed augmented tissue access in both in vitro and in vivo imaging. Some aptamers complexes and aptamers have been demonstrated to cross the blood-brain barrier and even enter cells. Base Pair has chosen aptamers for the ability to enter a particular type of cell. Production of monoclonal antibodies is a time-consuming and complex biological process. Fed-batch and perfusion culture processes have been created to boost yields and accelerate the bioproduction process. Still, culture contamination remains a concern, as an entire batch of material can be compromised because aptamers are chemically synthesized. Therefore, there is no risk of biological contamination and notable batch-to-batch good consistency. Also, information regarding the aptamer sequence and any modifications is needed to continue long-term access to the formerly produced and validated aptamer. Small DNA and RNA aptamers are fundamentally non-immunogenic, as demonstrated in numerous recent in vivo studies affecting aptamers. Therefore, they are suitable for in vivo use without extensive modification.

The “aptamers technology market” is segmented based on technique, type, applications, and end users. The aptamers technology market, by technique, is divided into SELEX Technique, MARAS, and Others based on technique. The SELEX technique segment dominated the market in 2022, and the same segment is expected to grow at its highest during the forecast period. The type segment of the global aptamers technology market consists of nucleic acid and peptide aptamers. The nucleic acid segment is further sub-segmented into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. The nucleic acid segment acquired the highest market value in 2022. Moreover, the same is expected to grow at the highest CAGR from 2022 to 2030.

The aptamers technology market, by application, is divided into diagnostics, therapeutics, research, and development. The diagnostics market dominated the market in 2022. By end user, the market is divided into biotechnology and pharmaceutical companies, academic and research institutions, and contract research organizations. In 2022, biotechnology and pharmaceutical companies are expected to hold significant market share and are estimated to retain their position over the forecast period.

Segmental Analysis:

The type segment of the global aptamers technology market consists of nucleic acid and peptide aptamers. A nucleic acid segment is further sub-segmented into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. The nucleic acid segment acquired the highest market value in 2022. DNA aptamers are inherently more stable, with lower manufacturing costs. RNA aptamers typically have more diverse three-dimensional conformations and stronger intra-strand RNA-RNA interactions, which probably increase binding affinity and specificity. One DNA aptamer (AS1411) and one L-form RNA aptamer (NOX-A12) have undergone clinical trials to treat cancers. AS1411, formerly named ARGO100 (Antisoma), is a 26-nt G-quadruplex DNA oligonucleotide (which was not evolved by classic SELEX204) and is the first aptamer in the clinical trials for the human cancer treatment.

By end user, the market is divided into biotechnology and pharmaceutical companies, academic and research institutions, and contract research organizations. In 2022, biotechnology and pharmaceutical companies are expected to hold significant market share and are estimated to retain their position over the forecast period. Factors propelling this segment's growth due to advancements in this sector. In February 2019, Base Pair Biotechnologies, Inc., The Aptamer Discovery CompanyTM, announced the award of an SBIR grant to develop aptamer-based POC tests for opioids to diagnose neonatal abstinence syndrome rapidly. The grant will be used to develop a new platform to detect opioids and their primary metabolites in newborns, enabling rapid treatment.

Furthermore, in October 2020, the company also announced that the company had been selected as a semi-finalist in the XPRIZE Rapid Covid Testing competition. Base Pair will use its proprietary aptamers in a novel electrochemical sensor to rapidly test saliva samples. As part of the competition, they will take inactivated viral antigen sample delivery and apply its test in a blinded fashion.

Regional Analysis - Aptamers Technology Market:

Based on geography, the global aptamer technology market is segmented into five regions: North America (US, Canada, and Mexico), Europe(UK, Germany, France, Italy, Spain, and rest of Europe), Asia Pacific (APAC) (Australia, China, India, South Korea, Japan, and Rest of Asia pacific), South & Central America (SCAM) (Brazil, Argentina, Rest of South & Central America), and the Middle East & Africa (MEA) (Saudi Arabia, South Africa, UAE, rest of Middle East & Africa).

In 2022, North America accounted for the most significant global aptamers technology market share. Asia Pacific is projected to grow faster, with the highest CAGR from 2022–2030.

North America holds the largest share of the surgical robot market. The market in this region is split into the US, Canada, and Mexico. The market growth in the region is growing due to the growing developments and advancements in the US and increasing FDA approvals. The US is the most significant contributor to the aptamers technology market in North America and the world.

As per the Centers for Disease Control and Prevention (CDC), in the US, age-related macular degeneration (AMD) has increased with age from 2% to 46.6% among people aged 40 to and aged ≥85. Respectively. Further, by state, the common prevalence of AMD ranged from low to high. For instance, a low of 6.2% in the District of Columbia and a high of 18.3% in Florida. This disease is usually associated with gathering undegraded waste around the retinal pigment epithelium, which is formed due to the repair and regeneration process of the eye. There are two forms of AMD, explicitly wet and dry AMD, preceding the central loss of vision. The ability of aptamers to be the panacea for most eye-related disorders is huge. US-based company Creative Biolabs has determined an optimal aptamer development platform and has massive experience in aptamer application research. Also, the company can provide global customers with comprehensive aptamer development services to promote project success.

A variety of nucleic acid-based therapies have been developed against macular degeneration worldwide. For instance, in September 2023, The FDA approved Iveric Bio/Astellas’s avacincaptad pegol (Izervay) for geographic atrophy (GA) secondary to age-related macular degeneration. The drug is the second RNA aptamer to gain FDA approval and the second complement-targeted drug for this cause of blindness.

Industry Developments and Future Opportunities - Aptamers Technology Market:  

Various initiatives taken by leading players operating in the Aptamers Technology market are listed below:

1. In June 2023, Aptamer Group and Neuro-Bio Collaborated to Develop an Alzheimer’s Disease Diagnostic Test. Aptamer Group, the developer of novel Optimer binders, and Neuro-Bio, an Oxford-based biotechnology company, announced the development of Optimer binders to allow a lateral flow test for the early diagnosis of Alzheimer’s disease on June 14, 2023. Partners at Neuro-Bio have patented the binders after their performance in specifically binding to the target biomarker and functionality in a nasal mucous matrix.
2. In March 2021, Aptamer Group, the Optimer reagents and therapeutics developer, announced an extension with AstraZeneca, a global biopharmaceutical company. This agreement evaluates the potential of using Optimer-based strategies to target renal cells and explores the feasibility of next-generation drug delivery vehicles, Optimer-drug conjugates. This agreement extension will further allow Aptamer Group’s expertise and knowledge in developing aptamer-based technologies with AstraZeneca’s leadership in developing cardiovascular, renal, and metabolic (CVRM) therapy.
3. In October 2023, Zentek Ltd., an intellectual property technology development and commercialization company, announced the launch of a wholly-owned subsidiary that will own the exclusive, global licensing rights for all aptamer-based technology from collaborating with McMaster University. This licensing agreement includes the rapid-detection platform and the recent aptamer-based platform technology developed by Dr. Yingfu Li and his team that is showing promise as a therapeutic through preclinical studies conducted by Dr. Matthew Miller and his team.
4. In March 2023, Aptamer Group plc, the novel Optimer binders developer to enable innovation in the life sciences industry, announced its new reagent, Optimer-Fc, for use in automated immunohistochemistry (IHC) workflows. The company is working with one of the top three companies within the IHC market to validate the performance of Optimer-Fc within their automated IHC platform. It is currently negotiating with two top 10 pharmaceutical companies seeking to trial Optimer-Fc.

Competitive Landscape and Key Companies - Aptamers Technology Market:

SomaLogic; Aptamer Group; Aptadel Therapeutics; Base Pair Biotechnologies; Noxxon Pharma; Vivonics Inc.; Aptagen, LLC; TriLink Biotechnologies; Altermune LLC; AM Biotechnologies; market companies. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.